Helicobacter Pylori First-Line and Rescue Treatments in the Presence of Penicillin Allergy

被引:48
作者
Gisbert, Javier P. [1 ]
Barrio, Jesus [2 ]
Modolell, Ines [3 ]
Molina-Infante, Javier [4 ]
Perez Aisa, Angeles [5 ]
Castro-Fernandez, Manuel [6 ,7 ]
Rodrigo, Luis [8 ]
Cosme, Angel [9 ,10 ]
Luis Gisbert, Jose [1 ]
Fernandez-Bermejo, Miguel [4 ]
Marcos, Santiago [1 ]
Marin, Alicia C. [1 ]
McNicholl, Adrian G. [1 ]
机构
[1] Hosp Univ La Princesa, Dept Gastroenterol, Inst Invest Sanitaria Princesa IP, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid 28669, Spain
[2] Hosp Rio Hortega, Dept Gastroenterol, Valladolid, Spain
[3] Consorci Sanitari Terrassa, Dept Gastroenterol, Barcelona, Spain
[4] Hosp San Pedro Alcantara, Dept Gastroenterol, Caceres, Spain
[5] Agencia Sanitaria Costa Sol, Dept Gastroenterol, Malaga, Spain
[6] Hosp Valme, Dept Gastroenterol, Seville, Spain
[7] CIBEREHD, Seville, Spain
[8] Univ Oviedo, Hosp Cent Asturias, Dept Gastroenterol, E-33080 Oviedo, Spain
[9] Hosp Donostia, Dept Gastroenterol, San Sebastian, Spain
[10] CIBEREHD, San Sebastian, Spain
关键词
Eradication; Helicobacter pylori; Bismuth; Levofloxacin; Quinolone; Allergic; Allergy; Penicillin; PROTON PUMP INHIBITOR; TRIPLE THERAPY; TREATMENT FAILURE; ANTIBIOTIC-RESISTANCE; QUADRUPLE THERAPY; INFECTION; LEVOFLOXACIN; ERADICATION; METRONIDAZOLE; CLARITHROMYCIN;
D O I
10.1007/s10620-014-3365-2
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Helicobacter pylori eradication is a challenge in penicillin allergy. To assess the efficacy and safety of first-line and rescue treatments in patients allergic to penicillin. Prospective multicenter study. Patients allergic to penicillin were given a first-line treatment comprising (a) 7-day omeprazole-clarithromycin-metronidazole and (b) 10-day omeprazole-bismuth-tetracycline-metronidazole. Rescue treatments were as follows: (a) bismuth quadruple therapy; (b) 10-day PPI-clarithromycin-levofloxacin; and (c) 10-day PPI-clarithromycin-rifabutin. Eradication was confirmed by C-13-urea breath test. Compliance was determined through questioning and recovery of empty medication envelopes. Adverse effects were evaluated by questionnaires. In total, 267 consecutive treatments were included. (1) First-line treatment: Per-protocol and intention-to-treat eradication rates with omeprazole-clarithromycin-metronidazole were 59 % (62/105; 95 % CI 49-62 %) and 57 % (64/112; 95 % CI 47-67 %). Respective figures for PPI-bismuth-tetracycline-metronidazole were 75 % (37/49; 95 % CI 62-89 %) and 74 % (37/50; 95 % CI (61-87 %) (p < 0.05). Compliance with treatment was 94 and 98 %, respectively. Adverse events were reported in 14 % with both regimens (all mild). (2) Second-line treatment: Intention-to-treat eradication rate with omeprazole-clarithromycin-levofloxacin was 64 % both after triple and quadruple failure; compliance was 88-100 %, with 23-29 % adverse effects (all mild). (3) Third-/fourth-line treatment: Intention-to-treat eradication rate with PPI-clarithromycin-rifabutin was 22 %. In allergic to penicillin patients, a first-line treatment with a bismuth-containing quadruple therapy (PPI-bismuth-tetracycline-metronidazole) seems to be a better option than the triple PPI-clarithromycin-metronidazole regimen. A levofloxacin-based regimen (together with a PPI and clarithromycin) represents a second-line rescue option in the presence of penicillin allergy.
引用
收藏
页码:458 / 464
页数:7
相关论文
共 37 条
[1]   Levofloxacin - A review of its use as a high-dose, short-course treatment for bacterial infection [J].
Anderson, Vanessa R. ;
Perry, Caroline M. .
DRUGS, 2008, 68 (04) :535-565
[2]   7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity [J].
Antos, D ;
Schneider-Brachert, W ;
Bästlein, E ;
Hänel, C ;
Haferland, C ;
Buchner, M ;
Meier, E ;
Trump, F ;
Stolte, M ;
Lehn, N ;
Bayerdörffer, E .
HELICOBACTER, 2006, 11 (01) :39-45
[3]   A 10-Day Levofloxacin-Based Therapy in Patients With Resistant Helicobacter pylori Infection: A Controlled Trial [J].
Bilardi, Claudio ;
Dulbecco, Pietro ;
Zentilin, Patrizia ;
Reglioni, Simona ;
Iiritano, Elena ;
Parodi, Andrea ;
Accornero, Laura ;
Savarino, Edoardo ;
Mansi, Carlo ;
Mamone, Mario ;
Vigneri, Sergio ;
Savarino, Vincenzo .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (11) :997-1002
[4]   Levofloxacin - A review of its use in the treatment of bacterial infections in the United States [J].
Croom, KF ;
Goa, KL .
DRUGS, 2003, 63 (24) :2769-2802
[5]  
De Francesco V, 2010, J GASTROINTEST LIVER, V19, P409
[6]   Meta-analysis:: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori [J].
Fischbach, L. ;
Evans, E. L. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (03) :343-357
[7]   Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin [J].
Furuta, Takahisa ;
Sugimoto, Mitsushige ;
Yamade, Mihoko ;
Uotani, Takahiro ;
Sahara, Shu ;
Ichikawa, Hitomi ;
Kagami, Takuma ;
Yamada, Takanori ;
Osawa, Satoshi ;
Sugimoto, Ken ;
Watanabe, Hiroshi ;
Umemura, Kazuo .
INTERNAL MEDICINE, 2014, 53 (06) :571-575
[8]   The Evolution of Helicobacter pylori Antibiotics Resistance Over 10 Years in Beijing, China [J].
Gao, Wen ;
Cheng, Hong ;
Hu, Fulian ;
Li, Jiang ;
Wang, Lihui ;
Yang, Guibin ;
Xu, Le ;
Zheng, Xiaoli .
HELICOBACTER, 2010, 15 (05) :460-466
[9]   A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses [J].
Gatta, L ;
Zullo, A ;
Perna, F ;
Ricci, C ;
De Francesco, V ;
Tampieri, A ;
Bernabucci, V ;
Cavina, M ;
Hassan, C ;
Ierardi, E ;
Morini, S ;
Vaira, D .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (01) :45-49
[10]   Review article: rifabutin in the treatment of refractory Helicobacter pylori infection [J].
Gisbert, J. P. ;
Calvet, X. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (02) :209-221